| Bid | 9.22 |
| Market Cap | 527.66M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -12.89 |
| PE Ratio (ttm) | -0.71 |
| Forward PE | n/a |
| Analyst | Sell |
| Ask | 9.29 |
| Volume | 92,733 |
| Avg. Volume (20D) | 1,286,185 |
| Open | 8.99 |
| Previous Close | 8.56 |
| Day's Range | 8.99 - 9.26 |
| 52-Week Range | 5.26 - 64.40 |
| Beta | undefined |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Bi...
Analyst Forecast
According to 5 analyst ratings, the average rating for DNA stock is "Sell." The 12-month stock price forecast is $10, which is an increase of 8.93% from the latest price.
Next Earnings Release
Analysts project revenue of $44.43M, reflecting a 27.84% YoY growth and earnings per share of -2.44, making a -44.55% decrease YoY.
2 months ago · seekingalpha.com
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call TranscriptGinkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2024 Results Conference Call November 12, 2024 5:30 PM ET Company Participants Megan LeDuc - Manager, IR Jason Kelly - Founder, CEO & Director Mark Dmytru...
